A Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study to Evaluate the Effect of Sacubitril-valsartan (LCZ696) Versus Enalapril on Changes in NT-proBNP and Safety and Tolerability of In-hospital Initiation of LCZ696 Compared to Enalapril in HFrEF Patients Who Have Been Stabilized Following Hospitalization for Acute Decompensated Heart Failure (ADHF).
Phase of Trial: Phase IV
Latest Information Update: 10 Mar 2017
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Enalapril
- Indications Decompensated heart failure
- Focus Therapeutic Use
- Acronyms PIONEER-HF
- Sponsors Novartis
- 07 Jun 2017 Biomarkers information updated
- 19 May 2016 Status changed from not yet recruiting to recruiting.
- 19 May 2016 Planned End Date changed from 1 Jun 2017 to 1 Apr 2018.